Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaap Fransen

Showing results (71-80 of 108) with videos related to

Pageof 11
Sort By:
Rheumatology (Oxford, England)|November 17, 2010
Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring registerWietske Kievit, Jaap Fransen, Eddy M M Adang, et al.
The Journal of Rheumatology|November 23, 2006
Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective studyAlfons A den Broeder, Marjonne C W Creemers, Jaap Fransen, et al.
Trials|September 1, 2017
Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trialAlfons A den Broeder, Lise M Verhoef, Jaap Fransen, et al.
Annals of the Rheumatic Diseases|March 14, 2007
Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritisAntoine W T van Lieshout, Jaap Fransen, Marcel Flendrie, et al.
Plos One|August 1, 2015
The Additive Value of Femoral Ultrasound for Subclinical Atherosclerosis Assessment in a Single Center Cohort of 962 Adults, Including High Risk Patients with Rheumatoid Arthritis, Human Immunodeficiency Virus Infection and Type 2 Diabetes MellitusAthanasios D Protogerou, Jaap Fransen, Evangelia Zampeli, et al.
The Journal of Rheumatology|May 16, 2021
Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis SubsetsTatiana Nevskaya, Janet E Pope, Matthew A Turk, et al.
Arthritis Care & Research|November 5, 2011
Validation of potential classification criteria for systemic sclerosisSindhu R Johnson, Jaap Fransen, Dinesh Khanna, et al.
Annals of the Rheumatic Diseases|April 26, 2007
Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritisTimothy R D J Radstake, Jaap Fransen, Erik J M Toonen, et al.
Annals of the Rheumatic Diseases|August 14, 2012
Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registrySanne A A van Dartel, Jaap Fransen, Wietske Kievit, et al.
Rheumatology (Oxford, England)|February 1, 2013
Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registrySanne A A van Dartel, Jaap Fransen, Wietske Kievit, et al.
Pageof 11

Showing results (71-80 of 108) with videos related to

Sort By:
Pageof 11
Rheumatology (Oxford, England)|November 17, 2010
Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring registerWietske Kievit, Jaap Fransen, Eddy M M Adang, et al.
The Journal of Rheumatology|November 23, 2006
Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective studyAlfons A den Broeder, Marjonne C W Creemers, Jaap Fransen, et al.
Trials|September 1, 2017
Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trialAlfons A den Broeder, Lise M Verhoef, Jaap Fransen, et al.
Annals of the Rheumatic Diseases|March 14, 2007
Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritisAntoine W T van Lieshout, Jaap Fransen, Marcel Flendrie, et al.
Plos One|August 1, 2015
The Additive Value of Femoral Ultrasound for Subclinical Atherosclerosis Assessment in a Single Center Cohort of 962 Adults, Including High Risk Patients with Rheumatoid Arthritis, Human Immunodeficiency Virus Infection and Type 2 Diabetes MellitusAthanasios D Protogerou, Jaap Fransen, Evangelia Zampeli, et al.
The Journal of Rheumatology|May 16, 2021
Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis SubsetsTatiana Nevskaya, Janet E Pope, Matthew A Turk, et al.
Arthritis Care & Research|November 5, 2011
Validation of potential classification criteria for systemic sclerosisSindhu R Johnson, Jaap Fransen, Dinesh Khanna, et al.
Annals of the Rheumatic Diseases|April 26, 2007
Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritisTimothy R D J Radstake, Jaap Fransen, Erik J M Toonen, et al.
Annals of the Rheumatic Diseases|August 14, 2012
Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registrySanne A A van Dartel, Jaap Fransen, Wietske Kievit, et al.
Rheumatology (Oxford, England)|February 1, 2013
Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registrySanne A A van Dartel, Jaap Fransen, Wietske Kievit, et al.
Pageof 11